Navigation Links
CELEXION Awarded Patent on Biosynthesis of Renewable Chemicals
Date:3/14/2012

CAMBRIDGE, Mass., March 14, 2012 /PRNewswire-iReach/ -- CELEXION LLC today announced the issuance of US Patent number 8,133,704 by the US Patent and Trademark Office entitled "Biological synthesis of difunctional alkanes from carbohydrate feedstocks."  The patent was issued on March 13, 2012 and covers biological methods of converting renewable feedstocks into a variety of high-value chemicals with a total market value of over $10B.

"At CELEXION, we leverage the power of biological systems to make new, high performance products and to make everyday products more functional, affordable, and sustainable," said Dr. Brian M. Baynes, CEO of CELEXION and co-inventor of the technology.  "The methods disclosed in this patent enable a variety of important bulk chemicals to be synthesized from renewable starting materials using biological catalysts.  The efficiency of this approach makes our products not only sustainable, but also less expensive than their petroleum-derived equivalents."

Claims of the '704 patent include key biosynthetic steps from common metabolic intermediates and their uses in manufacturing a family of chemicals including adipic acid, caprolactam, hexamethylenediamine, pimelic acid, and caprolactone.  These chemicals are key components in a wide variety of packaging, materials, polymers, and other industrial and consumer applications.

About CELEXION
CELEXION LLC is a bioengineering company that develops powerful platform technologies and products for partners in the pharmaceutical, industrial, agricultural, and consumer sectors. The company's technologies include the SECANT platform for engineering high performance protein products, a library of human antibodies for therapeutic lead generation, enzymatic pathways for synthesis of a variety of high-value chemicals and materials from wastes and other inexpensive precursors, and a novel family of enzymes for manipulation of chromosome-sized DNA.  CELEXION is headquartered in Cambridge, MA, USA.  For further information, please visit our website at www.celexionbio.com.

CELEXION and SECANT are registered trademarks of Celexion LLC.

Media Contact: Celexion Business Development, Celexion LLC, +1-617-500-3011 x1, info@celexionbio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE CELEXION LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chemring Detection Systems Awarded $9M for Biological Detection Systems
2. Leading German Researcher Awarded Elseviers 2011 Tetrahedron Prize
3. Chemring Detection Systems Awarded $500k for Strategic Research and Development
4. Telome Health Co-founder and Nobel Laureate Elizabeth Blackburn Awarded Innovator of the Year
5. Sloan Research Fellowships Awarded to 126 Young Scholars
6. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
7. Chinese Scientists Zhen-Yi Wang and Zhu Chen Awarded 7th Annual Szent-Gyorgyi Prize for Progress in Cancer Research
8. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
9. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
10. Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager
11. BioPower Systems Awarded $5 Million from Victorian Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... August 15, 2017 , ... ... pharmaceutical and biotherapeutics development, announces the launch of the new NHS Agile ... gain kinetic binding data for a wide range of molecules, including small and ...
(Date:8/15/2017)... MA (PRWEB) , ... August 15, 2017 , ... Any ... need that has compromised these disciplines for more than half a century. Despite ... be counted. It is widely known that molecular tags developed for this purpose ...
(Date:8/15/2017)... ... ... The Conference Forum and The Trout Group will ... upcoming panels and events. The partnership culminates with the 4th Annual IO360° summit ... City. , “With our experience in producing the Immuno-Oncology 360° NYC event and The ...
(Date:8/15/2017)... ... August 15, 2017 , ... JULABO USA introduces its ... new website makes it easy to navigate through the site whether you’re in ... detailed product information, educational industry content and visit the company’s social media accounts, ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
Breaking Biology News(10 mins):